Five drugs have been banned by FDA against use in advanced prostate cancer treatment, as they have been found to silently increasing the risk of diabetes, heart disease and stroke, reports Medguru.

The drugs were used to suppress the production of testosterone, a hormone that indirectly helps relieve symptoms of advanced prostate cancer in androgen deprivation therapy.

Though the risk of diabetes and heart disease in men treated with the drugs appears to be low, FDA suggests patients should be regularly monitored for increased blood sugar or possible signs of heart damage.

However, doctors are always expected to review the patient’s medical history and are required to check for potential side effects prior to any treatment. It is also considered important that patients inform their doctor of diabetes, heart disease, a heart attack, or a stroke, before beginning treatment with any of these drugs.

Any history of high blood pressure, high cholesterol, or cigarette smoking should also be reported. Months back, the drugs including Eligard, Lupron, Trelstar, Viadur and Zoladex were reviewed and safety concerns were issued.

Although the drugs wouldn’t be totally pulled off from the market, they are asked to go with new labels.